Swiss ISCB Student Council

IntiQuan GmbH is a Basel based consulting company working in the area of model based drug development. Business started in December 2015 with one person and it has continuously grown to currently four full time people. Main areas of consulting work are modeling & simulation based data analysis tasks in order to support clients in regulatory interactions, and with internal decision making about the next steps in the drug development process. In addition, IntiQuan supports clients with improvement of internal business processes. Typical examples for projects are:

Elke Schaper is a bioinformatician turned climate change environmentalist. She co-founded the Swiss-based environmental fintech startup Carbon Delta where she currently heads the software engineering team. The Carbon Delta team identifies and analyzes the climate change resilience of publicly traded companies. To date, very little is known about the extent to which individual companies are exposed to climate change and the costs that they will face to adapt to these effects. Estimated financial losses from climate change range from US$2.5 to 72 trillion by 2060 - numbers which would even make the Bill Gates’ of our time shudder. To help investors understand and quantify these risks within their portfolio, Carbon Delta developed a software model to assess a company’s Climate Value-at-Risk (Climate VaR), thus how much of its market value is possibly affected by climate change. Our method uses big data analysis (heard that before have you?) and can be used to calculate the Climate VaR for thousands of equities and other asset classes. Three core risk scenarios are evaluated for calculating a company's overall Climate VaR: Emission regulations, extreme weather events, and the Paris Agreement's 2°C target.

Performing research leads to discoveries or inventions. In both cases, patents can be filed in order to secure the development of related products. This also gives the opportunity to researchers to create their own future. I will present my experience in (co-)creating spin-off Biotech companies that have very different structures. I will also present possible features of a patent, license and initial financial support particularly in the context of Switzerland.

ETH Zurich has been supporting the foundation of companies based on its research achievements since the 90’s. The objective is to turn such research results into marketable products and to create qualified jobs. This talk will give you an overview how founders will get support from ETH Zurich.